Abamectin B1b (Avermectin B1b) is a macrocyclic lactone containing an isopropyl reside in the 25-position broad anthelmintic activity. The oral administration of this formulation of avermectin B1 appeared to be highly efficacious against intestinal strongyles and Onchocera microfilaria. Avermectin B1b is a component of marketed and provided commercially Abamectin, which is used to control livestock parasitic nematodes. It is a broad-spectrum acaricide with additional insecticidal action on a limited number of insects. Abamectin acts on insects by increasing the membrane permeability to chloride ions, and it mainly stimulates the release of Ȗ-aminobutyric acid (GABA). The affected arthropod becomes paralysed, stops feeding, and dies after a few days. It exerts contact and stomach action, with limited plant systemic activity, but exhibits translaminar movement into treated leaves. Abamectin is also used as an anthelmintic drug in veterinary medicine.

Bremazocine, a kappa-opioid agonist has limited potential as a clinical analgesic, however, possesses a possible utility for the therapy of alcohol and drug addiction. It was shown that bremazocine-like drugs could lower intraocular pressure and to minimize ischemic damage, that could be used in the therapy of glaucoma and cardiovascular disease.

Palytoxin is the most potent marine toxin known that was isolated from a zoanthid of the genus Palythoa and Cyanobacteria (Trichodesmium). Palytoxin is a potent vasoconstrictor that damages the ionic gradient of the cells, causing cell death. This toxin has a strong potential for toxicity in humans and animals that is why it causes great concern worldwide. It is crucial to remove this toxin and start an aggressive topical therapy as soon as possible.

Tilivapram is a heterocyclylbenzamide derivative patented by Rhone-Poulenc Rorer Ltd as phosphodiesterase IV inhibitor.

MK-3207 represents the third CGRP receptor antagonist to display clinical efficacy in migraine trials. It is a potent CGRP receptor antagonist with IC50 and Ki of 0.12 nM and 0.022 nM, highly selective versus human AM1, AM2, CTR, and AMY3. MK-3207 had been in phase II clinical trials by Merck Sharp & Dohme for the treatment of migraine. But the company had discontinued the research due to asymptomatic liver test abnormalities in 2010.

LAUROLINIUM, a quaternary ammonium compound, is a cationic antimicrobial agent. It has a broad spectrum of activity against Gram‐positive and Gram‐negative bacteria, fungi, and protozoan Trichomonas vaginalis. It is suitable for use in the treatment of local infections, for the sterilization of skin areas and for general antiseptic purposes.

Ampyzine is a pyrazine derivative patented by Warner-Lambert Pharmaceutical Co. as a central nervous system stimulant.

Anatibant was a selective small-molecule antagonist of the bradykinin B2 receptor that was undergoing clinical development with Xytis and Fournier for the treatment of brain injuries. Anatibant reduces brain oedema in animal TBI models. Noserious toxicity was found in Phase 1 clinical trials. Following subcutaneous administration of clinically relevant doses, there were no systemic effects but there was pain, inflammation and nodule formation at the injection site. Anatibant inhibits the binding of BK to the B2 receptor. After subcutaneous injection Anatibant is bio-available and crosses the BBB.

Etorphine was the first potent opiate agonist employed primarily for use in non-domestic and wild species. Etorphine was 500 times as potent as morphine, with a very rapid onset and short duration of action. In morphine-dependent subjects, etorphine suppressed abstinence but for a shorter period than morphine. Etorphine is a full opiate agonist and binds to multiple opiate sites in the central nervous system. It is believed to produce its clinical effects through binding the µ-, δ-, and κ- opiate sites. It has a potent effect on depressing the respiratory centers of the CNS thus resulting in apnea being commonly seen in immobilized animals. Etorphine revolutionized the ability of biologists and veterinarians to safely capture and restrain many species that previously could not be handled. Etorphine is not currently commercially available due to lack of production by the manufacturer.